Table 2.
Outcomes of the univariate regression analyses of demographic and medical factors on the EORTC QLQ-BR23 domains: P values
| BI T4 | FP T4 | SF T4 | SE T4 | BS T4 | AS T4 | BI T5 | FP T5 | SF T5 | SE T5 | BS T5 | AS T5 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age | .002 | .025 | .001 | |||||||||
| Screening referral | .014 | .042 | ||||||||||
| STAI total score | .006 | <.001 | <.001 | .004 | .034 | .020 | <.001 | .011 | .008 | .022 | ||
| Adjuvant treatment | .016 | |||||||||||
| Chemotherapy | .001 | <.001 | .038 | |||||||||
| Radiotherapy | .003 | <.001 | ||||||||||
| Hormonal treatment | .029 | |||||||||||
| Type of surgery | .001 | .007 | .005 | <.001 | ||||||||
| Disease stage | .045 | .003 | ||||||||||
| Educational level | .017 | .018 | .012 | |||||||||
| Children | .017 | |||||||||||
| Work | ||||||||||||
| Partner | .007 | <.001 |
BI Body image, FP future perspective, SF sexual functioning, SE systemic therapy side-effects, BS breast symptoms, AS arm symptoms, T4 measurement 6 months after surgical treatment, T5 measurement 12 months after surgical treatment
Note: Only significant results are shown